Stem Cell Research Product to grow Red Blood Cells outside the Human Body
The product, called NANEX is available only for research use and has not been tested in humans.
- NANEX is engineered to essentially behave like bone marrow;
- With NANEX, researchers can expand hematopoietic stem cells which form blood and immune cells and are responsible for the renewal of blood, to study potential stem-cell based therapies, as well as grow new blood cells and blood vessels;
- Arteriocyte is conducting its own preclinical research using NANEX to develop therapies for blood diseases and ischemia, a shortage in blood supply to an organ;
- However, it’ll be about a year-and-a-half before beginning testing NANEX based products in humans while Arteriocyte ramps up manufacturing of the substance.
Arteriocyte has found that this culturing technology represents a potential broad platform technology which will be of value in drug, vaccine and diagnostic development for malaria, a blood-borne infection and leukemia, a blood-borne cancer.
- The NANEX technology was developed by Dr. Hai-Quan Mao of Johns Hopkins University.
Arteriocyte, a clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts, is developing proprietary stem cell and tissue engineering based therapies.
- Arteriocyte’s goal is to develop commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage) for disease where surgical interventions are inadequate.